These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 10327426)

  • 1. Neurometabolic effects of psilocybin, 3,4-methylenedioxyethylamphetamine (MDE) and d-methamphetamine in healthy volunteers. A double-blind, placebo-controlled PET study with [18F]FDG.
    Gouzoulis-Mayfrank E; Schreckenberger M; Sabri O; Arning C; Thelen B; Spitzer M; Kovar KA; Hermle L; Büll U; Sass H
    Neuropsychopharmacology; 1999 Jun; 20(6):565-81. PubMed ID: 10327426
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Psychopathological, neuroendocrine and autonomic effects of 3,4-methylenedioxyethylamphetamine (MDE), psilocybin and d-methamphetamine in healthy volunteers. Results of an experimental double-blind placebo-controlled study.
    Gouzoulis-Mayfrank E; Thelen B; Habermeyer E; Kunert HJ; Kovar KA; Lindenblatt H; Hermle L; Spitzer M; Sass H
    Psychopharmacology (Berl); 1999 Feb; 142(1):41-50. PubMed ID: 10102781
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of the hallucinogen psilocybin on covert orienting of visual attention in humans.
    Gouzoulis-Mayfrank E; Thelen B; Maier S; Heekeren K; Kovar KA; Sass H; Spitzer M
    Neuropsychobiology; 2002; 45(4):205-12. PubMed ID: 12097810
    [TBL] [Abstract][Full Text] [Related]  

  • 4. "Ecstasy"-induced changes of cerebral glucose metabolism and their correlation to acute psychopathology. An 18-FDG PET study.
    Schreckenberger M; Gouzoulis-Mayfrank E; Sabri O; Arning C; Zimny M; Zeggel T; Wagenknecht G; Kaiser HJ; Sass H; Buell U
    Eur J Nucl Med; 1999 Dec; 26(12):1572-9. PubMed ID: 10638409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Investigations on the effect of "ecstasy" on cerebral glucose metabolism: an 18-FDG PET study].
    Schreckenberger M; Gouzoulis-Mayfrank E; Sabri O; Arning C; Tuttass T; Schulz G; Kaiser HJ; Wagenknecht G; Sass H; Büll U
    Nuklearmedizin; 1998; 37(8):262-7. PubMed ID: 9868707
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies.
    Studerus E; Kometer M; Hasler F; Vollenweider FX
    J Psychopharmacol; 2011 Nov; 25(11):1434-52. PubMed ID: 20855349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Double-blind comparison of the two hallucinogens psilocybin and dextromethorphan: effects on cognition.
    Barrett FS; Carbonaro TM; Hurwitz E; Johnson MW; Griffiths RR
    Psychopharmacology (Berl); 2018 Oct; 235(10):2915-2927. PubMed ID: 30062577
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of psilocybin on time perception and temporal control of behaviour in humans.
    Wittmann M; Carter O; Hasler F; Cahn BR; Grimberg U; Spring P; Hell D; Flohr H; Vollenweider FX
    J Psychopharmacol; 2007 Jan; 21(1):50-64. PubMed ID: 16714323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Psilocybin disrupts sensory and higher order cognitive processing but not pre-attentive cognitive processing-study on P300 and mismatch negativity in healthy volunteers.
    Bravermanová A; Viktorinová M; Tylš F; Novák T; Androvičová R; Korčák J; Horáček J; Balíková M; Griškova-Bulanova I; Danielová D; Vlček P; Mohr P; Brunovský M; Koudelka V; Páleníček T
    Psychopharmacology (Berl); 2018 Feb; 235(2):491-503. PubMed ID: 29302713
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Positron emission tomography and fluorodeoxyglucose studies of metabolic hyperfrontality and psychopathology in the psilocybin model of psychosis.
    Vollenweider FX; Leenders KL; Scharfetter C; Maguire P; Stadelmann O; Angst J
    Neuropsychopharmacology; 1997 May; 16(5):357-72. PubMed ID: 9109107
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enantio-selective cognitive and brain activation effects of N-ethyl-3,4-methylenedioxyamphetamine in humans.
    Spitzer M; Franke B; Walter H; Buechler J; Wunderlich AP; Schwab M; Kovar KA; Hermle L; Grön G
    Neuropharmacology; 2001 Aug; 41(2):263-71. PubMed ID: 11489463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Entactogenic drugs "ecstasy" (MDMA), "eve" (MDE) and other ring-substituted methamphetamine derivatives. A new class of substances among illegal designer drugs?].
    Gouzoulis-Mayfrank E; Hermle L; Kovar KA; Sass H
    Nervenarzt; 1996 May; 67(5):369-80. PubMed ID: 9005345
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Psychological effects of MDE in normal subjects. Are entactogens a new class of psychoactive agents?
    Hermle L; Spitzer M; Borchardt D; Kovar KA; Gouzoulis E
    Neuropsychopharmacology; 1993 Feb; 8(2):171-6. PubMed ID: 8471129
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Two dose investigation of the 5-HT-agonist psilocybin on relative and global cerebral blood flow.
    Lewis CR; Preller KH; Kraehenmann R; Michels L; Staempfli P; Vollenweider FX
    Neuroimage; 2017 Oct; 159():70-78. PubMed ID: 28711736
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Psilocybin-Induced Decrease in Amygdala Reactivity Correlates with Enhanced Positive Mood in Healthy Volunteers.
    Kraehenmann R; Preller KH; Scheidegger M; Pokorny T; Bosch OG; Seifritz E; Vollenweider FX
    Biol Psychiatry; 2015 Oct; 78(8):572-81. PubMed ID: 24882567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Psilocybin--summary of knowledge and new perspectives.
    Tylš F; Páleníček T; Horáček J
    Eur Neuropsychopharmacol; 2014 Mar; 24(3):342-56. PubMed ID: 24444771
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Not imagining it. Research into hallucinogens cautiously resumes.
    Biello D
    Sci Am; 2006 Nov; 295(5):33-5. PubMed ID: 17076078
    [No Abstract]   [Full Text] [Related]  

  • 18. Lifetime use of MDMA/ecstasy and psilocybin is associated with reduced odds of major depressive episodes.
    Jones GM; Nock MK
    J Psychopharmacol; 2022 Jan; 36(1):57-65. PubMed ID: 34983261
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Methodological issues of human experimental research with hallucinogens.
    Gouzoulis-Mayfrank E; Schneider F; Friedrich J; Spitzer M; Thelen B; Sass H
    Pharmacopsychiatry; 1998 Jul; 31 Suppl 2():114-8. PubMed ID: 9754843
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of psilocybin on cognitive and emotional functions in healthy participants: Results from a phase 1, randomised, placebo-controlled trial involving simultaneous psilocybin administration and preparation.
    Rucker JJ; Marwood L; Ajantaival RJ; Bird C; Eriksson H; Harrison J; Lennard-Jones M; Mistry S; Saldarini F; Stansfield S; Tai SJ; Williams S; Weston N; Malievskaia E; Young AH
    J Psychopharmacol; 2022 Jan; 36(1):114-125. PubMed ID: 35090363
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.